◀ Back to MAPK3
APC — MAPK3
Text-mined interactions from Literome
da Silva et al., Anesthesiology 2004
(Reperfusion Injury) :
IPC but not
APC markedly
activated ERK1/2 and p38
MAPK , which were abrogated by coadministration of the specific blockers ... Conversely, IPC and
APC enhanced ERK1/2 activity after ischemia-reperfusion as compared to nonpreconditioned hearts, and IPC in addition
enhanced p38
MAPK activity
Bretschneider et al., Circ Res 2007
(Carotid Stenosis) :
APC induced
ERK-1/2 phosphorylation was inhibited by an anti-EPCR antibody and by a cleavage site blocking anti-PAR-1 antibody, indicating that binding of APC to EPCR and cleavage of protease activated receptor-1 (PAR-1) were involved
O'Brien et al., Arterioscler Thromb Vasc Biol 2007
:
APC also
induced a significant increase in phosphorylation of
ERK-1/2 , required to activate EGR-1 expression
Menschikowski et al., Thromb Res 2008
(Inflammation) :
At the same time,
APC increased the phosphorylation of
ERK 1/2 and decreased NF-kappaB and C/EBP-beta DNA binding activities in these cells, as compared with respective stimulated controls ... Application of antibodies against EPCR and protease activated receptor-1 (PAR-1) reduced the
APC induced
ERK 1/2 activation and the treatment of cells with a PAR-1 antagonist diminished the sPLA ( 2 ) -IIA inhibition
Wang et al., Front Biosci (Elite Ed) 2011
(Brain Ischemia) :
APC with sevofurane markedly improved neurological performance of stroke rats, significantly decreased infarct volume, and robustly
suppressed activation of NF-kappa B and p38
MAPK , and expression of inflammatory cytokines
Caro-Gonzalez et al., J Cell Sci 2012
:
Mitogen activated protein kinase (
MAPK/ERK )
regulates adenomatous polyposis coli during growth-factor induced cell extension